Help accelerate Southern Research's work against COVID-19.

Learn More

Antibiotic/Antibacterial Vaccine Development


The continued rise of antibiotic resistance requires new approaches to the prevention and treatment of bacterial infections. Unfortunately, it can be difficult to find a contract research partner willing to collaborate and develop supporting assays and animal models that are necessary to move novel ideas forward. That’s where Southern Research stands apart from other service providers. Our experienced scientists will take your unique needs into consideration in the context of the ever-changing regulatory landscape for antibacterial drugs, biologics and vaccines and will work with you to identify and implement the most promising development strategy.

Working with Southern Research is straightforward and convenient. Our service capabilities span the entire continuum from early stage, hit-to-lead verification all the way to late stage, clinical trial support. We have in-house bioanalytical, immunoassay, histopathology, and toxicology capabilities to support a wide range of needs quickly and confidently. Most services can be conducted under GLP regulatory compliance, when necessary. Click here for a full listing of our services.



  • A variety of in vitro panels for resistance testing, efficacy studies and custom screening
  • Unique experience with Sexually Transmitted Infection (STI) pathogens
    • Neisseria gonorrhoeae MIC 90 panel with multidrug resistant (MDR) clinical isolates
    • Unique Chlamydia trachomatis mouse model and in vitro support services
    • Various in vitro capabilities for Mycoplasma genitalium and bacterial vaginosis (BV) pathogen (Gardnerella vaginals, Mobiluncus spp., Atopobium vaginae) efficacy testing
  • Pre-assembled MIC panels including ESKAPE, MDR, CRE, ESBL, CF, Respiratory, STI, Bacterial Meningitis, Gastroenteritis, Pseudomonas, Klebsiella, Acinetobacter, Staphylococcus, and Wound Infection panels including CDC strains and MDR clinical isolates.
  • Wound Infection pathogens
    • Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus MIC 90 panels with MDR clinical isolates
    • Skin infection mouse model
    • Surgical Site infection mouse model
    • Wound infection mouse model
  • Biofilm inhibition and eradication assays
  • Customizable animal models for efficacy and pharmacokinetics/pharmacodynamics (PK/PD)

Meet Our Team Members

Nathan Fisher, Ph.D., MBA | Senior Business Development Executive

As associate director of bacteriology, Nathan Fisher, Ph.D., leads a team of scientists dedicated to combating the rising threat of antimicrobial resistance with state-of-the-art drug discovery and development capabilities. Fisher joined Southern Research in 2015, as project leader within the Infectious Disease Research program, where he established several new animal models including the first small animal preclinical model for human Chlamydia trachomatis isolates to be offered by a CRO. He quickly advanced to senior project leader and then associate director. From 2012-2015, Fisher was an assistant professor at North Dakota State University. Between 2010 and 2012, he worked as principal investigator at the Genomic Center National Biodefense Analysis & Countermeasure Center, where he designed and managed a dynamic research program to address knowledge gaps within the Biological Threat Risk Assessment for BSL-3 select agent bacteria. From 2006-2010 he was principal investigator, Bacteriology Division, at the U.S. Army Medical Research Institute of Infectious Disease, where he managed a variety of projects funded by the Department of the Army and the Defense Threat Reduction Agency to understand the molecular pathogenesis of Bacillus anthracis and Francisella tularensis.